IRWD
Ironwood Pharmaceuticals, Inc. Class A · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website ironwoodpharma.com
- Employees(FY) 219
- ISIN US46333X1081
Performance
+3.05%
1W
+0.74%
1M
-45.39%
3M
-11.74%
6M
-29.02%
YTD
-22.74%
1Y
Profile
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Investment Analysis Report: IRWD
Overview
In this investment analysis report, we will delve into a comprehensive analysis of IRWD, a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating ...
Technical Analysis of IRWD 2024-05-03
Overview:
In analyzing the technical indicators for IRWD over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2024-05-06 16:01
- 2024-05-06 04:01
- 2024-05-02 13:34
- 2024-05-02 10:01
- 2024-05-02 02:33
- 2024-05-01 22:01
- 2024-05-01 07:30
- 2024-04-30 19:30
- 2024-04-30 13:16
- 2024-04-30 01:16
- 2024-04-25 16:01
- 2024-04-25 04:01
- 2024-04-23 20:00
IRWD: Raising target price to $9.00(Argus Research)
- 2024-04-20 22:39
5 Best Low Price Pharma Stocks To Invest In(Insidermonkey)
- 2024-03-28 07:30
- 2024-03-27 19:30
- 2024-03-25 09:57
- 2024-03-05 13:05
It’s Time! 3 Failing Biotech Stocks to Sell Right Now(InvestorPlace)
- 2024-02-29 16:19
Ironwood Pharmaceuticals Ran Up 38% Over Three Months — And Just Lost It All(Investor's Business Daily)
- 2024-02-29 06:26
- 2024-02-29 06:08
- 2024-02-29 06:00
- 2024-02-28 19:37
Why Is Ironwood Pharmaceuticals (IRWD) Stock Down 27% Today?(Investorplace)
- 2024-02-28 17:00
- 2024-02-23 07:30
- 2024-02-22 18:30
- 2024-02-17 07:50
- 2024-02-16 10:15
- 2024-02-16 09:36
- 2024-02-15 22:45
Q4 2023 Ironwood Pharmaceuticals Inc Earnings Call(Thomson Reuters StreetEvents)
Page 1 of 5
previousnext